Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (Q46482643)
Jump to navigation
Jump to search
scientific article published on 12 April 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study |
scientific article published on 12 April 2017 |
Statements
1 reference
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (English)
1 reference
William J Sandborn
1 reference
Brian G Feagan
1 reference
Geert D'Haens
1 reference
Stefan Schreiber
1 reference
Edouard Louis
1 reference
Marc Ferrante
1 reference
Ursula Seidler
1 reference
Markus F Neurath
1 reference
Olivier Dewit
1 reference
Julián Panés
1 reference
Arthur Kaser
1 reference
Denis Franchimont
1 reference
Kyung-Jo Kim
1 reference
Paul Scholl
1 reference
Chandrasena Pamulapati
1 reference
Bojan Lalovic
1 reference
Sudha Visvanathan
1 reference
Steven J Padula
1 reference
Ivona Herichova
1 reference
Adina Soaita
1 reference
David B Hall
1 reference
Wulf O Böcher
1 reference
12 April 2017
1 reference
1 reference
389
1 reference
10080
1 reference
1699-1709
1 reference